The Fontan operation is now among the most common procedures performed to treat complex congenital cardiac defects not amenable to biventricular repair. The advent of the Norwood procedure to treat ...

In the current issue of Cardiovascular Innovations and Applications, researchers Ahmed Kheiwa, Anushree Agarwal and Anitha John from the Division of Cardiology, Department of Medicine, University of ...

Of the thousands of children born each year with congenital heart defects, a small cohort have severe malformations of their cardiac chambers leading to a single ventricle physiology. The current ...

DALLAS, July 1, 2019 -- The Fontan procedure has allowed more people born with only one ventricle -- the lower pumping chamber of the heart -- to survive into adulthood, but their unique circulatory ...

CCHMC is building a new learning network to assess long-term complications of a procedure for people born with a variety of congenital heart defects. A doctor at Cincinnati Children’s Hospital Medical ...

A multi-center study has identified critical risk factors that increase the likelihood of death in children with a heart defect who are awaiting or have recently undergone heart transplantation, ...

Mezzion Pharmaceuticals, Inc. (Mezzion), a late-stage rare disease biopharmaceutical company developing the first potential ...

SEOUL, South Korea, June 30, 2020 /PRNewswire/ -- Mezzion Pharma Co. Ltd. (140410.KQ), announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) ...

Twenty years after the publication of Fontan's landmark article, he and his colleagues [16] warned about the long-term results of the Fontan operation, expressing the fear that continuing attrition ...